Multivariable logistic regression model estimating the odds ratio of targeted therapy utilization based on patient characteristics (2014–19 sensitivity analysis)
| Covariates | Odds ratio (95% CI) | P value |
| Race and ethnicity (reference=Non-Hispanic white) | ||
| Non-Hispanic black | 0.82 (0.60 to 1.12) | 0.21 |
| Asian | 0.89 (0.63 to 1.24) | 0.49 |
| Hispanic | 0.82 (0.63 to 1.07) | 0.15 |
| Other and unknown | 0.30 (0.09 to 0.98) | 0.046 |
| Age group at diagnosis (reference=65–69 years) | ||
| 70–74 | 0.90 (0.75 to 1.07) | 0.23 |
| 75–79 | 0.63 (0.52 to 0.76) | <0.001 |
| 80–84 | 0.53 (0.43 to 0.67) | <0.001 |
| ≥85 | 0.40 (0.30 to 0.52) | <0.001 |
| Year of diagnosis (reference=2014) | ||
| 2015 | 1.06 (0.85 to 1.33) | 0.23 |
| 2016 | 1.17 (0.94 to 1.47) | 0.17 |
| 2017 | 1.46 (1.16 to 1.84) | 0.001 |
| 2018 | 1.46 (1.15 to 1.84) | 0.002 |
| 2019 | 1.22 (0.96 to 1.54) | 0.10 |
| Region at diagnosis (reference=Midwest region) | ||
| Northeast | 1.43 (1.07 to 1.90) | 0.015 |
| South | 1.62 (1.21 to 2.17) | 0.001 |
| West | 1.61 (1.21 to 2.16) | 0.001 |
| Charlson Comorbidity Index (reference=0) | ||
| 1 | 0.93 (0.79 to 1.10) | 0.40 |
| ≥2 | 0.75 (0.63 to 0.90) | 0.002 |